GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

The FDA granted accelerated approval to Ultragenyx's Genglycos, the first gene therapy for glycogen storage disease type Ia (GSDIa), establishing new precedents for manufacturing scale-up, long-term post-marketing surveillance, and treatment centre qualification in ultra-rare disease gene therapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 19 Aug 2026 and 22 Aug 2026.